Marksans Pharma Ltd. (NSE: MARKSANS, BSE: 524404) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹13,001 Cr, it ranks #488 by market cap among the 6,189 Indian listed companies on FinBizNet, and #10 of 63 in Pharmaceuticals. At ₹286.90 (as of 26 Oct 2026), the share price is 18.3% below its 52-week high of ₹350.95 and 85.1% above its 52-week low of ₹155.00. The share price is up 61.1% over one year and up 16.5% over three months.
| Current Price | ₹286.90 |
|---|---|
| Market Cap | ₹13,001 Cr |
| NSE Symbol | MARKSANS |
| BSE Code | 524404 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 31.1 |
| Return on Equity | 25.45% |
| Return on Assets | 8.85% |
| 52-Week Range | ₹155.00 – ₹350.95 |
| 1-Year Price Change | +61.1% |
| 3-Month Price Change | +16.5% |
| Beta (1Y) | 0.72 |
| Dividend Yield | 0.31% |
| Headquarters | Mumbai, Maharashtra |
| Website | marksanspharma.com |
| Revenue | ₹841 Cr |
|---|---|
| Net Profit | ₹159 Cr |
| Net Margin | 19.0% |
| EPS (Basic) | ₹3.47 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
1. Bulk Drugs Division-This segment engages in manufacturing pharmaceutical formulations. 2. Formulations Division-This segment engages in the manufacture and sale of bulk drugs. 3. Research, Manufacturing and Marketing of Pharmaceutical Formulation-This segment engages in the manufacture and sale of formulations and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹53,132 Cr | 34.2 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,028 Cr | 38.9 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹33,581 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹25,398 Cr | -77.7 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹23,578 Cr | 93 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹16,891 Cr | 26.4 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹16,525 Cr | 22.9 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,199 Cr | 24.2 | 18.07% | ₹873 Cr | -30.8% |
| Marksans Pharma Ltd. | ₹13,001 Cr | 31.1 | 25.45% | ₹841 Cr | +61.1% |
Listed by market capitalisation. Ratios are shown for context only.
Marksans Pharma Ltd. is trading at ₹286.90, with a market capitalisation of ₹13,001 Cr.
Marksans Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Marksans Pharma Ltd. has a P/E of 31.1 and a return on equity of 25.45%.
Marksans Pharma Ltd. is listed on the NSE under the symbol MARKSANS and on the BSE under the scrip code 524404.
Marksans Pharma Ltd.'s share price is up 61.1% over one year and up 16.5% over three months. Its 52-week range is ₹155.00 to ₹350.95.
In Q1 FY27, Marksans Pharma Ltd. reported revenue of ₹841 Cr and net profit of ₹159 Cr, with basic EPS of ₹3.47 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.